Fingolimod (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fingolimod" in English language version.

refsWebsite

Global rank English rank

26nih.gov

4^th place

21doi.org

2^nd place

11semanticscholar.org

11^th place

8^th place

8web.archive.org

1^st place

3europa.eu

68^th place

117^th place

3fda.gov

447^th place

338^th place

2harvard.edu

18^th place

17^th place

2fiercepharma.com

low place

8,921^st place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1drugs.com

399^th place

333^rd place

1uptodate.com

3,771^st place

2,605^th place

1webmd.com

1,169^th place

1,075^th place

1ms-uk.org

low place

1aao.org

low place

7,618^th place

1jbc.org

4,455^th place

5,199^th place

1researchgate.net

120^th place

125^th place

1vancouversun.com

2,017^th place

1,154^th place

1news-medical.net

8,069^th place

7,681^st place

1novartis.com

low place

1uscourts.gov

2,275^th place

1,288^th place

1supremecourt.gov

3,811^th place

2,160^th place

1reuters.com

49^th place

47^th place

1neurosciencenews.com

low place

aao.org

development.aao.org

Jain N, Bhatti MT (April 2012). "Macular Edema Associated With Fingolimod" (PDF). EyeNet. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356. Archived from the original (PDF) on 16 June 2016. Retrieved 20 August 2015.

canada.ca

"Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.

doi.org

Sanford M (August 2014). "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis". Drugs. 74 (12): 1411–33. doi:10.1007/s40265-014-0264-y. PMID 25063048. S2CID 42807019.
Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C (March 2009). "Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report". Neurology. 72 (11): 1022–4. doi:10.1212/01.wnl.0000344567.51394.e3. PMID 19289744. S2CID 8523513.
Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, et al. (March 2022). "Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature". Journal of Neurology. 269 (3): 1678–1687. doi:10.1007/s00415-021-10910-1. PMID 34800168.
Jain N, Bhatti MT (February 2012). "Fingolimod-associated macular edema: incidence, detection, and management". Neurology. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356.
Jain N, Bhatti MT (April 2012). "Macular Edema Associated With Fingolimod" (PDF). EyeNet. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356. Archived from the original (PDF) on 16 June 2016. Retrieved 20 August 2015.
Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S (November 2003). "The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2". FEBS Letters. 554 (1–2): 189–93. Bibcode:2003FEBSL.554..189P. doi:10.1016/S0014-5793(03)01168-2. PMID 14596938. S2CID 41465940.
Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T (November 2003). "Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases". The Journal of Biological Chemistry. 278 (48): 47408–15. doi:10.1074/jbc.M307687200. PMID 13129923. Free full text Archived 13 June 2008 at the Wayback Machine
Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, et al. (November 2003). "Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability". The Journal of Biological Chemistry. 278 (47): 47281–90. doi:10.1074/jbc.M306896200. PMID 12954648.
Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ (November 2001). "Lysophospholipids--receptor revelations". Science. 294 (5548): 1875–8. Bibcode:2001Sci...294.1875H. doi:10.1126/science.1065323. PMID 11729304. S2CID 46727063.
Ntranos A, Hall O, Robinson DP, Grishkan IV, Schott JT, Tosi DM, et al. (May 2014). "FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway". Journal of Neuroimmunology. 270 (1–2): 13–21. doi:10.1016/j.jneuroim.2014.03.007. PMID 24680062. S2CID 206276944.
Schilling T, Miralles F, Eder C (November 2014). "TRPM7 regulates proliferation and polarisation of macrophages". Journal of Cell Science. 127 (Pt 21): 4561–6. doi:10.1242/jcs.151068. PMC 4215710. PMID 25205764.
Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, et al. (July 2006). "Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor". Molecular Pharmacology. 70 (1): 41–50. doi:10.1124/mol.105.020552. PMID 16571654. S2CID 11131541.
Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, et al. (February 2007). "The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors". Blood. 109 (3): 1077–85. doi:10.1182/blood-2006-03-011437. PMC 1785128. PMID 17008548.
Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek SM, et al. (February 2009). "FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells". The Journal of Biological Chemistry. 284 (9): 5467–77. doi:10.1074/jbc.M805186200. PMC 2645812. PMID 19119142.
Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH (June 2009). "Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner". The Journal of Biological Chemistry. 284 (24): 16090–8. doi:10.1074/jbc.M807438200. PMC 2713526. PMID 19357080.
Horga A, Montalban X (May 2008). "FTY720 (fingolimod) for relapsing multiple sclerosis". Expert Review of Neurotherapeutics. 8 (5): 699–714. doi:10.1586/14737175.8.5.699. PMID 18457527. S2CID 28071687.
Adachi K, Chiba K (September 2007). "FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology". Perspectives in Medicinal Chemistry. 1: 11–23. doi:10.1177/1177391X0700100002. PMC 2754916. PMID 19812733.
Fujita T, Yoneta M, Hirose R, Sasaki S, Inoue K, Kiuchi M, et al. (1995). "Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity". Bioorg. Med. Chem. Lett. 5 (8): 847–52. doi:10.1016/0960-894X(95)00126-E.
Balasubramaniam S, Sankaran GS, Badle SS (2018). "Perspective on FTY720, an Immunosuppressant". Synthesis. 50 (5): 968–83. doi:10.1055/s-0036-1591877. S2CID 102682294.
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G (April 2016). "Fingolimod for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2016 (4): CD009371. doi:10.1002/14651858.CD009371.pub2. PMC 10401910. PMID 27091121.
Testa S, Haabeth OA, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, et al. (July 2022). "Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro". Biomacromolecules. 23 (7): 2976–2988. doi:10.1021/acs.biomac.2c00469. PMC 10199726. PMID 35748182. S2CID 249989444.

drugs.com

"Fingolimod Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 9 August 2015.

europa.eu

ema.europa.eu

"Gilenya EPAR". European Medicines Agency (EMA). 17 March 2011. Retrieved 16 November 2024.
"Updated restrictions for Gilenya: multiple sclerosis medicine not to be used in pregnancy". European Medicines Agency (EMA) (Press release). 26 July 2019. Retrieved 12 July 2020. This article incorporates text from this source, which is in the public domain.
"EMA approval information about Gilenya". Archived from the original on 14 April 2018. Retrieved 5 February 2022.

fda.gov

"FDA approves first generics of Gilenya". U.S. Food and Drug Administration (FDA) (Press release). 5 December 2019. Archived from the original on 5 December 2019. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.
"FDA approves first oral drug to reduce MS relapses". U.S. Food and Drug Administration (FDA). 22 September 2010. Archived from the original on 14 February 2017. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Brand Name (Generic Name) NDA #". U.S. Food and Drug Administration (FDA). 5 December 2019. Archived from the original on 5 December 2019. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.

fiercepharma.com

Sagonowsky E (13 April 2017). "Novartis' Gilenya patent loss sets MS market up for battle with early generics". FiercePharma.
Kansteiner F (14 October 2022). "Novartis' blockbuster Gilenya exposed to generics in short term amid Supreme Court appeal". Fierce Pharma. Retrieved 17 October 2022.

harvard.edu

ui.adsabs.harvard.edu

Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S (November 2003). "The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2". FEBS Letters. 554 (1–2): 189–93. Bibcode:2003FEBSL.554..189P. doi:10.1016/S0014-5793(03)01168-2. PMID 14596938. S2CID 41465940.
Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ (November 2001). "Lysophospholipids--receptor revelations". Science. 294 (5548): 1875–8. Bibcode:2001Sci...294.1875H. doi:10.1126/science.1065323. PMID 11729304. S2CID 46727063.

jbc.org

Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T (November 2003). "Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases". The Journal of Biological Chemistry. 278 (48): 47408–15. doi:10.1074/jbc.M307687200. PMID 13129923. Free full text Archived 13 June 2008 at the Wayback Machine

ms-uk.org

"MS-UK | Multiple Sclerosis Information, Helpline, support, MS news and research". Archived from the original on 19 March 2015. Retrieved 17 June 2014.

neurosciencenews.com

"Unlocking the Mystery of "Chemo Brain"". 2 September 2022.

news-medical.net

"Novartis new MS treatment receives Notice of Compliance in Canada". NewsMedical.net. 10 March 2011.

nih.gov

pubmed.ncbi.nlm.nih.gov

Sanford M (August 2014). "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis". Drugs. 74 (12): 1411–33. doi:10.1007/s40265-014-0264-y. PMID 25063048. S2CID 42807019.
Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C (March 2009). "Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report". Neurology. 72 (11): 1022–4. doi:10.1212/01.wnl.0000344567.51394.e3. PMID 19289744. S2CID 8523513.
Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, et al. (March 2022). "Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature". Journal of Neurology. 269 (3): 1678–1687. doi:10.1007/s00415-021-10910-1. PMID 34800168.
Jain N, Bhatti MT (February 2012). "Fingolimod-associated macular edema: incidence, detection, and management". Neurology. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356.
Jain N, Bhatti MT (April 2012). "Macular Edema Associated With Fingolimod" (PDF). EyeNet. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356. Archived from the original (PDF) on 16 June 2016. Retrieved 20 August 2015.
Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S (November 2003). "The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2". FEBS Letters. 554 (1–2): 189–93. Bibcode:2003FEBSL.554..189P. doi:10.1016/S0014-5793(03)01168-2. PMID 14596938. S2CID 41465940.
Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T (November 2003). "Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases". The Journal of Biological Chemistry. 278 (48): 47408–15. doi:10.1074/jbc.M307687200. PMID 13129923. Free full text Archived 13 June 2008 at the Wayback Machine
Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, et al. (November 2003). "Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability". The Journal of Biological Chemistry. 278 (47): 47281–90. doi:10.1074/jbc.M306896200. PMID 12954648.
Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ (November 2001). "Lysophospholipids--receptor revelations". Science. 294 (5548): 1875–8. Bibcode:2001Sci...294.1875H. doi:10.1126/science.1065323. PMID 11729304. S2CID 46727063.
Ntranos A, Hall O, Robinson DP, Grishkan IV, Schott JT, Tosi DM, et al. (May 2014). "FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway". Journal of Neuroimmunology. 270 (1–2): 13–21. doi:10.1016/j.jneuroim.2014.03.007. PMID 24680062. S2CID 206276944.
Schilling T, Miralles F, Eder C (November 2014). "TRPM7 regulates proliferation and polarisation of macrophages". Journal of Cell Science. 127 (Pt 21): 4561–6. doi:10.1242/jcs.151068. PMC 4215710. PMID 25205764.
Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, et al. (July 2006). "Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor". Molecular Pharmacology. 70 (1): 41–50. doi:10.1124/mol.105.020552. PMID 16571654. S2CID 11131541.
Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, et al. (February 2007). "The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors". Blood. 109 (3): 1077–85. doi:10.1182/blood-2006-03-011437. PMC 1785128. PMID 17008548.
Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek SM, et al. (February 2009). "FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells". The Journal of Biological Chemistry. 284 (9): 5467–77. doi:10.1074/jbc.M805186200. PMC 2645812. PMID 19119142.
Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH (June 2009). "Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner". The Journal of Biological Chemistry. 284 (24): 16090–8. doi:10.1074/jbc.M807438200. PMC 2713526. PMID 19357080.
Horga A, Montalban X (May 2008). "FTY720 (fingolimod) for relapsing multiple sclerosis". Expert Review of Neurotherapeutics. 8 (5): 699–714. doi:10.1586/14737175.8.5.699. PMID 18457527. S2CID 28071687.
Adachi K, Chiba K (September 2007). "FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology". Perspectives in Medicinal Chemistry. 1: 11–23. doi:10.1177/1177391X0700100002. PMC 2754916. PMID 19812733.
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G (April 2016). "Fingolimod for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2016 (4): CD009371. doi:10.1002/14651858.CD009371.pub2. PMC 10401910. PMID 27091121.
Testa S, Haabeth OA, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, et al. (July 2022). "Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro". Biomacromolecules. 23 (7): 2976–2988. doi:10.1021/acs.biomac.2c00469. PMC 10199726. PMID 35748182. S2CID 249989444.

ncbi.nlm.nih.gov

Schilling T, Miralles F, Eder C (November 2014). "TRPM7 regulates proliferation and polarisation of macrophages". Journal of Cell Science. 127 (Pt 21): 4561–6. doi:10.1242/jcs.151068. PMC 4215710. PMID 25205764.
Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, et al. (February 2007). "The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors". Blood. 109 (3): 1077–85. doi:10.1182/blood-2006-03-011437. PMC 1785128. PMID 17008548.
Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek SM, et al. (February 2009). "FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells". The Journal of Biological Chemistry. 284 (9): 5467–77. doi:10.1074/jbc.M805186200. PMC 2645812. PMID 19119142.
Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH (June 2009). "Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner". The Journal of Biological Chemistry. 284 (24): 16090–8. doi:10.1074/jbc.M807438200. PMC 2713526. PMID 19357080.
Adachi K, Chiba K (September 2007). "FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology". Perspectives in Medicinal Chemistry. 1: 11–23. doi:10.1177/1177391X0700100002. PMC 2754916. PMID 19812733.
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G (April 2016). "Fingolimod for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2016 (4): CD009371. doi:10.1002/14651858.CD009371.pub2. PMC 10401910. PMID 27091121.
Testa S, Haabeth OA, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, et al. (July 2022). "Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro". Biomacromolecules. 23 (7): 2976–2988. doi:10.1021/acs.biomac.2c00469. PMC 10199726. PMID 35748182. S2CID 249989444.

novartis.com

"Novartis key multiple sclerosis product Gilenya approved in China". Novartis (Press release).

researchgate.net

Ntranos A, Hall O, Robinson DP, Grishkan IV, Schott JT, Tosi DM, et al. (May 2014). "FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway". Journal of Neuroimmunology. 270 (1–2): 13–21. doi:10.1016/j.jneuroim.2014.03.007. PMID 24680062. S2CID 206276944.

reuters.com

Brittain B (17 April 2023). "US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent". Reuters. Retrieved 18 April 2023.

semanticscholar.org

api.semanticscholar.org

Sanford M (August 2014). "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis". Drugs. 74 (12): 1411–33. doi:10.1007/s40265-014-0264-y. PMID 25063048. S2CID 42807019.
Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C (March 2009). "Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report". Neurology. 72 (11): 1022–4. doi:10.1212/01.wnl.0000344567.51394.e3. PMID 19289744. S2CID 8523513.
Jain N, Bhatti MT (February 2012). "Fingolimod-associated macular edema: incidence, detection, and management". Neurology. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356.
Jain N, Bhatti MT (April 2012). "Macular Edema Associated With Fingolimod" (PDF). EyeNet. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356. Archived from the original (PDF) on 16 June 2016. Retrieved 20 August 2015.
Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S (November 2003). "The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2". FEBS Letters. 554 (1–2): 189–93. Bibcode:2003FEBSL.554..189P. doi:10.1016/S0014-5793(03)01168-2. PMID 14596938. S2CID 41465940.
Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ (November 2001). "Lysophospholipids--receptor revelations". Science. 294 (5548): 1875–8. Bibcode:2001Sci...294.1875H. doi:10.1126/science.1065323. PMID 11729304. S2CID 46727063.
Ntranos A, Hall O, Robinson DP, Grishkan IV, Schott JT, Tosi DM, et al. (May 2014). "FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway". Journal of Neuroimmunology. 270 (1–2): 13–21. doi:10.1016/j.jneuroim.2014.03.007. PMID 24680062. S2CID 206276944.
Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, et al. (July 2006). "Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor". Molecular Pharmacology. 70 (1): 41–50. doi:10.1124/mol.105.020552. PMID 16571654. S2CID 11131541.
Horga A, Montalban X (May 2008). "FTY720 (fingolimod) for relapsing multiple sclerosis". Expert Review of Neurotherapeutics. 8 (5): 699–714. doi:10.1586/14737175.8.5.699. PMID 18457527. S2CID 28071687.
Balasubramaniam S, Sankaran GS, Badle SS (2018). "Perspective on FTY720, an Immunosuppressant". Synthesis. 50 (5): 968–83. doi:10.1055/s-0036-1591877. S2CID 102682294.
Testa S, Haabeth OA, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, et al. (July 2022). "Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro". Biomacromolecules. 23 (7): 2976–2988. doi:10.1021/acs.biomac.2c00469. PMC 10199726. PMID 35748182. S2CID 249989444.

supremecourt.gov

"Search - Supreme Court of the United States". U.S. Supreme Court. Retrieved 17 October 2022.

tga.gov.au

"FINGOLIMOD-TEVA/TE-FINGOLIMOD (Teva Pharma Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Retrieved 23 April 2023.

uptodate.com

"UpToDate". www.uptodate.com. Retrieved 24 June 2019.

uscourts.gov

oralarguments.cafc.uscourts.gov

"CAFC Oral Argument Recording".

vancouversun.com

First oral MS treatment approved for Canada https://vancouversun.com/health/First+oral+treatment+approved+Canada+says+drug+company/4420028/story.html Archived 27 April 2011 at the Wayback Machine

web.archive.org

"MS-UK | Multiple Sclerosis Information, Helpline, support, MS news and research". Archived from the original on 19 March 2015. Retrieved 17 June 2014.
Jain N, Bhatti MT (April 2012). "Macular Edema Associated With Fingolimod" (PDF). EyeNet. 78 (9): 672–80. doi:10.1212/WNL.0b013e318248deea. PMID 22371414. S2CID 11742356. Archived from the original (PDF) on 16 June 2016. Retrieved 20 August 2015.
"FDA approves first generics of Gilenya". U.S. Food and Drug Administration (FDA) (Press release). 5 December 2019. Archived from the original on 5 December 2019. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.
Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T (November 2003). "Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases". The Journal of Biological Chemistry. 278 (48): 47408–15. doi:10.1074/jbc.M307687200. PMID 13129923. Free full text Archived 13 June 2008 at the Wayback Machine
"FDA approves first oral drug to reduce MS relapses". U.S. Food and Drug Administration (FDA). 22 September 2010. Archived from the original on 14 February 2017. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Brand Name (Generic Name) NDA #". U.S. Food and Drug Administration (FDA). 5 December 2019. Archived from the original on 5 December 2019. Retrieved 5 December 2019. This article incorporates text from this source, which is in the public domain.
First oral MS treatment approved for Canada https://vancouversun.com/health/First+oral+treatment+approved+Canada+says+drug+company/4420028/story.html Archived 27 April 2011 at the Wayback Machine
"EMA approval information about Gilenya". Archived from the original on 14 April 2018. Retrieved 5 February 2022.

webmd.com

"Good News for Oral MS Drug Fingolimod". Webmd.com. 16 April 2008. Retrieved 30 September 2013.